Synthesis of 13, 492 Antisense Oligonucleotides (ASOs) for SARS-Cov2 Project
Closed Solicitation Posted
- Solicitation number
- 75N95022Q00339
- Agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- United States
Notice details come from SAM.gov. Updated .
About this opportunity
This solicitation seeks the synthesis of 13,492 antisense oligonucleotides for a SARS-CoV2 project from Integrated DNA Technologies, Inc. without full and open competition. The National Institutes of Health National Institute on Drug Abuse requires the oligonucleotides by July 5, 2022 to maintain scientific continuity with a long-term ongoing SARS-CoV2 study as Integrated DNA Technologies, Inc. previously synthesized the exact oligonucleotides. Responses are due by July 5, 2022 with an anticipated award date of July 8, 2022 and should include unit pricing, shipping costs, delivery terms, and product information.
There is no set-aside designation with NAICS code 325414 for this commercial item procurement under FAR Part 13. Integrated DNA Technologies, Inc. is identified as the potential incumbent due to synthesizing the oligonucleotides previously. The place of performance will be within the United States and responses should provide pricing and delivery details for the synthesis of 13,492 oligonucleotides to support the SARS-CoV2 study.
Notice text
*Please see attached non-competitive combined synopsis/solicitation*
Files
| File | Type | Posted |
|---|---|---|
| F_CSS_NonComp Posting.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| This notice | Solicitation | |
| Synthesis of 13, 492 Antisense Oligonucleotides (ASOs) for SARS-Cov2 Project | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| RNA sequencing and whole genome sequencing services | Office of Logisitics and Acquisition Operations | No set-aside | |
| NOI - DNA Sequencing of Bone Marrow Failure Syndro | Office of Logisitics and Acquisition Operations | No set-aside | |
| NOI - B2B Award entitled - Developing Red Cell-Sp | Office of Logisitics and Acquisition Operations | No set-aside | |
| DNA Sequencing Service | Office of Logisitics and Acquisition Operations | No set-aside | |
| Synthesis and Distribution of Drugs of Abuse and Related Compounds | National Institute on Drug Abuse | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity